Silo Pharma, Inc. (SILO) income statement
SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$1.89+0.18 (+10.53%)
Close on Nov 18, 2026Market cap $3.00MP/E –Yield –
Silo Pharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- -14.8%
- Operating margin
- -8250.5%
- Net margin
- -8269.5%
- Return on equity, FY2025
- -74.6%
Financial strength
- Current ratio
- 5.36
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 307.5%
Valuation
- P/E ratio
- –
- Price to sales
- 55.51
- Price to book
- 0.61
- Dividend yield
- –
See a number that looks wrong?